Validate Novel Targets & Utilize Biomarker-Driven Combination Strategies to Accelerate the Development of Durable, Selective & Low-Toxicity DDR Therapeutics
Returning to Boston for its 9th year, the DDR Inhibitors Summit is the definitive meeting for senior decision-makers driving innovation in DNA Damage Response (DDR)-targeted oncology. With PARP inhibitors clinically validated for almost a decade, the field is now on the cusp of the next inhibitor class approval. This is your chance to lead the charge in advancing novel targets such as ATR, CHK1/2, DNA-PK, WEE1, ALC1, WRN and Polθ, alongside smarter biomarker strategies and combination approaches.
Across three content-rich days, uncover translational breakthroughs, hear from 33 expert speakers, and gain strategic insights to overcome resistance, enhance selectivity and fast-track clinical success. With dedicated sessions on biomarker-driven patient selection, smarter DDR combinations with radiotherapy, chemotherapy, ADCs and radiopharmaceuticals, and academic–industry partnerships, this summit is your opportunity to stay ahead of the curve.
Join 80+ leaders from global pharma, pioneering biotechs and world-class academia, including C-Level executives, VPs, directors and senior scientists from organizations such as EMD Serono, Roche, Merck, Novartis, BMS, Artios Pharma, Breakpoint Therapeutics, Debiopharm, MD Anderson CancerCenter, University of Oxford and University of Pennsylvania.
With the DDR landscape rapidly expanding, now is the time to connect, collaborate and shape the future of targeted oncology.
The DDR field is approaching a critical point of validation, going beyond the first-generation PARP drugs, with many new agents in early development. Year on year, this conference brings together key leaders and decision-makers striving to advance this field to the benefit of underserved patients.
Jon Hollick, Managing Director & Head of Research, Breakpoint Therapeutics
This meeting provides practical knowledge of the opportunities and challenges in moving therapeutic concepts from basic research to clinical trials and patient benefit.
Eric Brown, Associate Professor & Scientific Consultant, University of Pennsylvania
The most important thing to me was being able to meet people working in essentially all areas of the drug development pipeline. I learned a lot and substantially expanded my network.
Grant Frost, Co-founder & Chief Scientist, Riptide Therapeutics
Explore the Full Event Guide
- 30+ expert speakers from leading biopharma, biotech, and academia
- 3 days of exclusive content, including a dedicated Biomarker Focus Day
- 80+ attendees focused exclusively on DDR-targeted drug development
- 1 Scientific Poster Session to showcase your latest research
- Unmissable sessions on enhancing patient stratification, optimizing combination strategies & overcoming resistance
Attending Companies Include
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join DDR Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.